The prevention and treatment of venous thromboembolism in pregnancy

Michela Villani, Walter Ageno, Elvira Grandone, Francesco Dentali

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: Venous thromboembolism (VTE) in pregnancy represents an important cause of maternal morbidity and mortality in developed countries, with an incidence of 0.5–2.2 per 1000 pregnancies. In addition to hemostatic changes occurring during normal pregnancy, several risk factors have been identified. Thus, a variety of clinical conditions as well as fetal and maternal risks linked to a possible anticoagulant therapy should be considered for the management of VTE during pregnancy. Unfortunately, there is a paucity of high-quality evidence from randomized trials in this field, and current recommendations are based on observational studies or evidence gathered from studies in the non-pregnant population. Areas covered: The purpose of this review is to summarize available evidence on the prevention and treatment of pregnancy-related VTE. Expert commentary: Although the optimal prophylactic and therapeutic dosage has not yet been established, low-molecular-weight heparin (LMWH) represents the most efficacious and safe anticoagulant during pregnancy. Thus, after an accurate risk stratification of women during pregnancy and puerperium, LMWH should be recommended to women at risk for VTE and to those ones suffering from an acute event.

Original languageEnglish
Pages (from-to)397-402
Number of pages6
JournalExpert Review of Cardiovascular Therapy
Volume15
Issue number5
DOIs
Publication statusPublished - May 4 2017

Fingerprint

Venous Thromboembolism
Pregnancy
Low Molecular Weight Heparin
Anticoagulants
Therapeutics
Maternal Mortality
Hemostatics
Developed Countries
Postpartum Period
Observational Studies
Mothers
Morbidity
Incidence
Population

Keywords

  • Heparin
  • postpartum period
  • pregnancy
  • thromboprophylaxis
  • venous thromboembolism

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

The prevention and treatment of venous thromboembolism in pregnancy. / Villani, Michela; Ageno, Walter; Grandone, Elvira; Dentali, Francesco.

In: Expert Review of Cardiovascular Therapy, Vol. 15, No. 5, 04.05.2017, p. 397-402.

Research output: Contribution to journalReview article

@article{624d4432ecda4dfb88228eb42e0d3f5a,
title = "The prevention and treatment of venous thromboembolism in pregnancy",
abstract = "Introduction: Venous thromboembolism (VTE) in pregnancy represents an important cause of maternal morbidity and mortality in developed countries, with an incidence of 0.5–2.2 per 1000 pregnancies. In addition to hemostatic changes occurring during normal pregnancy, several risk factors have been identified. Thus, a variety of clinical conditions as well as fetal and maternal risks linked to a possible anticoagulant therapy should be considered for the management of VTE during pregnancy. Unfortunately, there is a paucity of high-quality evidence from randomized trials in this field, and current recommendations are based on observational studies or evidence gathered from studies in the non-pregnant population. Areas covered: The purpose of this review is to summarize available evidence on the prevention and treatment of pregnancy-related VTE. Expert commentary: Although the optimal prophylactic and therapeutic dosage has not yet been established, low-molecular-weight heparin (LMWH) represents the most efficacious and safe anticoagulant during pregnancy. Thus, after an accurate risk stratification of women during pregnancy and puerperium, LMWH should be recommended to women at risk for VTE and to those ones suffering from an acute event.",
keywords = "Heparin, postpartum period, pregnancy, thromboprophylaxis, venous thromboembolism",
author = "Michela Villani and Walter Ageno and Elvira Grandone and Francesco Dentali",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/14779072.2017.1319279",
language = "English",
volume = "15",
pages = "397--402",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - The prevention and treatment of venous thromboembolism in pregnancy

AU - Villani, Michela

AU - Ageno, Walter

AU - Grandone, Elvira

AU - Dentali, Francesco

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: Venous thromboembolism (VTE) in pregnancy represents an important cause of maternal morbidity and mortality in developed countries, with an incidence of 0.5–2.2 per 1000 pregnancies. In addition to hemostatic changes occurring during normal pregnancy, several risk factors have been identified. Thus, a variety of clinical conditions as well as fetal and maternal risks linked to a possible anticoagulant therapy should be considered for the management of VTE during pregnancy. Unfortunately, there is a paucity of high-quality evidence from randomized trials in this field, and current recommendations are based on observational studies or evidence gathered from studies in the non-pregnant population. Areas covered: The purpose of this review is to summarize available evidence on the prevention and treatment of pregnancy-related VTE. Expert commentary: Although the optimal prophylactic and therapeutic dosage has not yet been established, low-molecular-weight heparin (LMWH) represents the most efficacious and safe anticoagulant during pregnancy. Thus, after an accurate risk stratification of women during pregnancy and puerperium, LMWH should be recommended to women at risk for VTE and to those ones suffering from an acute event.

AB - Introduction: Venous thromboembolism (VTE) in pregnancy represents an important cause of maternal morbidity and mortality in developed countries, with an incidence of 0.5–2.2 per 1000 pregnancies. In addition to hemostatic changes occurring during normal pregnancy, several risk factors have been identified. Thus, a variety of clinical conditions as well as fetal and maternal risks linked to a possible anticoagulant therapy should be considered for the management of VTE during pregnancy. Unfortunately, there is a paucity of high-quality evidence from randomized trials in this field, and current recommendations are based on observational studies or evidence gathered from studies in the non-pregnant population. Areas covered: The purpose of this review is to summarize available evidence on the prevention and treatment of pregnancy-related VTE. Expert commentary: Although the optimal prophylactic and therapeutic dosage has not yet been established, low-molecular-weight heparin (LMWH) represents the most efficacious and safe anticoagulant during pregnancy. Thus, after an accurate risk stratification of women during pregnancy and puerperium, LMWH should be recommended to women at risk for VTE and to those ones suffering from an acute event.

KW - Heparin

KW - postpartum period

KW - pregnancy

KW - thromboprophylaxis

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85018921338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018921338&partnerID=8YFLogxK

U2 - 10.1080/14779072.2017.1319279

DO - 10.1080/14779072.2017.1319279

M3 - Review article

C2 - 28425765

AN - SCOPUS:85018921338

VL - 15

SP - 397

EP - 402

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 5

ER -